98%
921
2 minutes
20
Primary aldosteronism, characterized by the dysregulated production of aldosterone from 1 or both adrenal glands, is the most common endocrine cause of hypertension. It confers a high risk of cardiovascular, renal, and metabolic complications that can be ameliorated with targeted medical therapy or surgery. Diagnosis can be achieved with a positive screening test (elevated aldosterone to renin ratio) followed by confirmatory testing (saline, captopril, fludrocortisone, or oral salt challenges) and subtyping (adrenal imaging and adrenal vein sampling). However, the diagnostic pathway may be complicated by interfering medications, intraindividual variations, and concurrent autonomous cortisol secretion. Furthermore, once diagnosed, careful follow-up is needed to ensure that treatment targets are reached and adverse effects, or even recurrence, are promptly addressed. These challenges will be illustrated in a series of case studies drawn from our endocrine hypertension clinic. We will offer guidance on strategies to facilitate an accurate and timely diagnosis of primary aldosteronism together with a discussion of treatment targets which should be achieved for optimal patient outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181003 | PMC |
http://dx.doi.org/10.1210/jendso/bvae109 | DOI Listing |
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, Zydus Cancer Hospital, Ahmedabad, Gujarat, India.
Primary aldosteronism (PA) is one of the prevalent causes of secondary hypertension, characterized by the autonomous hypersecretion of aldosterone and concurrent renin inhibition. Clinical and biochemical remission rates for patients with PA achieved through surgery are far higher compared to those achieved through drug treatment; hence, subtyping PA is crucial for identifying patients who will benefit most from surgery. Computed tomography (CT) scan with adrenal protocol and adrenal venous sampling (AVS) is used conventionally for PA subtype classification.
View Article and Find Full Text PDFMini Rev Med Chem
September 2025
Department of PET/CT Diagnostic Imaging, Tianjin Medical University General Hospital, Tianjin 300052, China.
The diagnosis of adrenocortical tumors remains clinically challenging due to overlapping morphological and functional features between benign, malignant, and hormonally active lesions. Malignant and functional tumors are frequently associated with poor prognosis. Traditional morphological imaging methods, such as CT and MRI, cannot reliably distinguish lesion types.
View Article and Find Full Text PDFInt J Surg
September 2025
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Eur J Endocrinol
September 2025
Endocrinology & Nutrition Department. Hospital Universitario Ramón y Cajal Madrid, Spain & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain.
Objective: The indication for laparoscopic partial adrenalectomy (LPA) in patients with primary aldosteronism due to aldosterone-producing adenoma (APA) remains controversial. This study aimed to determine the functional and surgical outcomes of LPA in this context.
Methods: This is a systematic review and meta-analysis.
Front Mol Biosci
August 2025
Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Recent advances in artificial intelligence (AI) are reshaping the diagnostic and therapeutic of primary aldosteronism (PA). For screening, machine learning models integrate multidimensional data to improve the efficiency of PA detection, facilitating large-scale population screening. For diagnosis, AI-driven algorithms have further enhanced the specificity of PA identification.
View Article and Find Full Text PDF